Accumulation of peptidoglycan O-acetylation leads to altered cell wall biochemistry and negatively impacts pathogenesis factors of <em>Campylobacter jejuni</em> by Ha R et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Ha R, Frirdich E, Sychantha D, Biboy J, Taveirne ME, Johnson JG, DiRita VJ, 
Vollmer W, Clarke AJ, Gaynor EC.  
Accumulation of peptidoglycan O-acetylation leads to altered cell wall 
biochemistry and negatively impacts pathogenesis factors  
of Campylobacter jejuni.  
Journal of Biological Chemistry 2016, 291, 22686-22702. 
 
Copyright: 
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc. 
Author's Choice—Final version free via Creative Commons CC-BY license. 
  
DOI link to article: 
http://dx.doi.org/10.1074/jbc.M116.746404  
Date deposited:   
02/11/2016 
Accumulation of PeptidoglycanO-Acetylation Leads to
Altered Cell Wall Biochemistry and Negatively Impacts
Pathogenesis Factors of Campylobacter jejuni*□S
Received for publication, July 8, 2016 Published, JBC Papers in Press, July 29, 2016, DOI 10.1074/jbc.M116.746404
Reuben Ha‡1, Emilisa Frirdich‡, David Sychantha§, Jacob Biboy¶, Michael E. Taveirne2, Jeremiah G. Johnson3,
Victor J. DiRita4, Waldemar Vollmer¶, Anthony J. Clarke§, and Erin C. Gaynor‡5
From the ‡Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia V6T 1Z3,
Canada, the §Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario N1G 2W1, Canada, the ¶Centre
for Bacterial Cell Biology, Institute for Cell andMolecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 4AX,
United Kingdom, and the Department of Microbiology and Immunology, University of MichiganMedical School,
Ann Arbor, Michigan 48109
Campylobacter jejuni is a leading cause of bacterial gastroen-
teritis in the developed world. Despite its prevalence, its mech-
anisms of pathogenesis are poorly understood. Peptidoglycan
(PG) is important for helical shape, colonization, and host-
pathogen interactions in C. jejuni. Therefore, changes in PG
greatly impact the physiology of this organism.O-acetylation of
peptidoglycan (OAP) is a bacterial phenomenon proposed to be
important for proper cell growth, characterized by acetylation
of the C6 hydroxyl group of N-acetylmuramic acid in the PG
glycan backbone. The OAP gene cluster consists of a PG
O-acetyltransferase A (patA) for translocation of acetate into
the periplasm, a PG O-acetyltransferase B (patB) for O-acetyla-
tion, and an O-acetylpeptidoglycan esterase (ape1) for de-O-
acetylation. In this study, reducedOAP inpatA andpatBhad
minimal impact on C. jejuni growth and fitness under the con-
ditions tested. However, accumulation of OAP in ape1
resulted in marked differences in PG biochemistry, including
O-acetylation, anhydromuropeptide levels, and changes not
expected to result directly fromApe1 activity. This suggests that
OAP may be a form of substrate level regulation in PG biosyn-
thesis. Ape1 acetylesterase activity was confirmed in vitro using
p-nitrophenyl acetate and O-acetylated PG as substrates. In addi-
tion, ape1 exhibited defects in pathogenesis-associated pheno-
types, including cell shape,motility, biofilm formation, cell surface
hydrophobicity, and sodium deoxycholate sensitivity. ape1 was
also impaired for chick colonization and adhesion, invasion, intra-
cellular survival, and induction of IL-8 production in INT407 cells
in vitro. The importance of Ape1 in C. jejuni biology makes it a
good candidate as an antimicrobial target.
Campylobacter jejuni is a leading bacterial cause of food-
borne gastroenteritis in the developedworld and themost com-
mon infectious antecedent to the autoimmune acute polyneu-
ropathy Guillain-Barre´ syndrome (1, 2). As a commensal of the
avian gut, it is a prevalent contaminant of uncooked poultry (3).
Because of its high incidence rate, the costs ofC. jejuni infection
are a significant socioeconomic burden,making it both a health
care concern and an economic issue (4). In addition, C. jejuni
has been exhibiting alarming increases in resistance to cipro-
floxacin and erythromycin, the most commonly used antibiot-
ics for treatment of C. jejuni infection (5). Despite its preva-
lence, relatively little is known about C. jejuni pathogenesis in
humans. Traditional virulence factors present in other gastro-
intestinal pathogens are either absent (i.e. dedicated type III
secretion systems) or limited (C. jejuni possesses some stress-
response elements such as the stringent response modulator
SpoT, but it lacks several hallmark stress-response elements
like RpoS and RpoE), or their role in pathogenicity is debated
(i.e. the cytolethal distending toxin and a putative type IV secre-
tion system on the pVIR plasmid) (6–11). However, factors
considered to be fundamental aspects of bacterial physiology
such as metabolism, stress response, and cell shape are hypoth-
esized to play important roles inC. jejuni pathogenesis (12, 13).
The peptidoglycan (PG)6 sacculus is a heteropolymer of the
bacterial cell wall composed of alternating -1–4 N-acetylglu-
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cosamine (GlcNAc) andN-acetylmuramic acid (MurNAc) res-
idues cross-linked to adjacent strands by peptides bound to the
MurNAc residue. It is responsible for providing structural
strength to the cell, enabling it to resist changes in osmotic
pressure, and for maintenance of cell shape (14–16). The cork-
screw motility of C. jejuni generated by its helical shape and
polar flagella is thought to be important in enhancing its ability
tomove through viscousmedia, such as themucous layer of the
gastrointestinal tract (14, 17). Deletion of PG hydrolase
enzymes Pgp1 and Pgp2 in C. jejuni has led to a change in mor-
phology from helical to straight with accompanying defects in
traits associated with pathogenesis, including motility in soft
agar, biofilm formation, and chick colonization. PG isolated
from pgp1 and pgp2 also exhibited altered stimulation of
host cell NOD receptors, and pgp1 elicits an enhanced pro-
inflammatory IL-8 response from INT407 epithelial cells upon
infection (18, 19). Changes in PG biosynthesis and composition
as well as the release of PG products have long been known to
affect physiological and pathogenic properties of many bacte-
rial species (20), includingListeriamonocytogenes (21, 22),Heli-
cobacter pylori (23), and Streptococcus pneumoniae (24). Cur-
rent research continues to support this concept (15). Some
recent studies have shown that changes in morphology and PG
structure in Mycobacterium tuberculosis affect its physiology
and virulence in mice (25); changes in morphology in Proteus
mirabilis affect its swarmingmotility (26); and changes inmor-
phology in Helicobacter pylori alter its motility and coloniza-
tion potential (27, 28).
Understanding PGbiosyntheticmechanisms inC. jejunimay
prove advantageous to the development of new antimicrobials.
It has been suggested that O-acetylation of peptidoglycan
(OAP) machinery may be an attractive target (29–33). OAP
occurs in both Gram-positive and Gram-negative bacteria and
is characterized by the addition of an acetyl group to the C6
hydroxyl group of MurNAc in the PG glycan backbone (Fig.
1A). This modification confers resistance to lysozyme (34, 35),
which cleaves -1,4-glycosidic bonds between MurNAc and
GlcNAc (36). Despite the intrinsic resistance to lysozyme pro-
vided by the outer membrane of Gram-negative bacteria,
lysozyme resistance was shown to be important in H. pylori
using mutants defective in OAP addition and similar glycan
modifications (37). These strains showed increased susceptibil-
ity to physiologically relevant concentrations of lysozyme in the
presence of the host lactoferrin, which has membrane permea-
bilization properties (38, 39). O-Acetylated gonococcal PG is
implicated in the development of arthritic symptoms and is
hypothesized to be attributable to increasedPGhydrolase resis-
tance leading to large fragments of circulating PG (40). In addi-
tion, OAP is believed to be involved in the regulation of PG
turnover by inhibiting endogenous lytic transglycosylase (LT)
activity. LTs require an unmodifiedMurNAcC6 hydroxyl moi-
ety to cleave -1,4-glycosidic bonds between MurNAc and
GlcNAc, generating anhydromuropeptides (anhMPs). LTs are
therefore important for generating insertion sites for newly
synthesizedmuropeptides during cell growth and division (41).
The OAP gene cluster was initially identified in Neisseria
gonorrhoeae and was found to be responsible for OAP in many
Gram-negative pathogens (42). It consists of a putative trans-
membrane protein, PGO-acetyltransferase A (PatA) predicted
to be involved in the translocation of acetyl moieties from a
cytoplasmic source into the periplasm, a periplasmic transfer-
ase, PG O-acetyltransferase B responsible for O-acetylation of
MurNAc, and a periplasmic O-acetylpeptidoglycan esterase
(Ape1) for MurNAc de-O-acetylation (Fig. 1A and B) (42–44).
Since their discovery, PatB and Ape1 from N. gonorrhoeae and
Neisseria meningitidis have been well characterized biochemi-
cally, including descriptions of the catalytic residues, mecha-
nism of enzyme activity, and substrate specificity (30, 32, 43,
45). The availability of a recently solved crystal structure for
N. meningitidis Ape1, recently identified Ape1 inhibitors, and
studies showing reduced septicemia in mice infected with
N. meningitidis ape1 mutants lend support for the application
of Ape1 as an antimicrobial target (31, 33, 46).
C. jejuni encodes previously unstudied homologs of theOAP
genes patA, patB, and ape1. In this work, the roles of these
genes in PG O-acetylation and overall PG biosynthesis, as well
as biological and pathogenic attributes were assessed via con-
struction of strains deleted for each or all of these genes fol-
lowed by biochemical and phenotypic analyses. Each mutant
exhibited changes in PG O-acetylation consistent with pre-
dicted gene product functions. The accumulation of O-acety-
lated PG was found to be detrimental to C. jejuni fitness,
whereas diminishedO-acetylation had little to no effect.ape1
exhibited defects in PG muropeptide composition, cell mor-
phology, pathogenic attributes, and host-pathogen interac-
tions, whereas patA, patB, and oap mutants exhibited no
or, in rare cases, only minimal defects for these phenotypes.
Results
C. jejuni OAP Genes Were Identified by BLAST and Mutant
and Complemented Strains Were Generated—The OAP gene
cluster was identified in C. jejuni 81-176 wild type by BLAST
analysis using the N. gonorrhoeae OAP gene sequences.
The loci identified were cjj81176_0640, cjj81176_0639, and
cjj81176_0638 for patA, patB, and ape1, respectively (Fig. 1B).
Amino acid sequence identity and sequence similarity for these
genes were 35/53%, 39/57%, and 26/44% identity/similarity to
N. gonorrhoeae patA, patB, and ape1, respectively.
To investigate the role of OAP in C. jejuni, the patA, patB,
and ape1 homologs, as well as the entire gene cluster, were
inactivated by deletion-insertionmutagenesis with the non-po-
lar KmR cassette (aphA-3) from pUC18K-2 lacking a transcrip-
tional termination site (Fig. 1C; supplemental text S1) (47).
Complementation was achieved using the pRRC integration
vector (48). For complementation, the coding region of each
OAP gene plus upstream sequence containing the ribosomal
binding site was inserted into the genome of the corresponding
mutant at ribosomal intergenic regions along with a CmR cas-
sette (the ape1 complemented strain, designated ape1C, is
shown in Fig. 1D as an example). Expression of the wild-type
genes at the rRNA site was driven from the promoter of the
CmR cassette.
Growth rate experiments performed on all mutant strains
indicated no significant difference in growth rates in broth cul-
tures up to 36 h (data not shown) with the exception ofape1C,
which grew at a slower rate (although this slower growth rate
Role of C. jejuni Peptidoglycan O-Acetylation
OCTOBER 21, 2016•VOLUME 291•NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 22687
 at N
ew
castle U
niversity on N
ovem
ber 2, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
did not affect the ability of ape1C to complement ape1 phe-
notypes). Differences were observed in the long term survival
properties ofape1withmoremodest differences exhibited by
patA, patB, oap, and ape1C.At 48 h, a 1.0-log increase in
recovery was observed for ape1, but recovery fell at 72 h by
0.8-log relative to wild type. At 48 h, patA and patB exhib-
ited a 0.3-log increase, and oap showed a 0.4-log increase in
recovery, relative to wild type. The recovery of all three OAP-
deficient mutants was 0.3-log lower than wild type at 72 h.
ape1C exhibited a 0.8-log increase in recovery at 48 h and a
0.3-log decrease at 72 h relative to wild type (data not shown).
O-Acetylation Levels of Purified PG from Deletion Mutants
Reflect the Putative Functions of the C. jejuni OAP Gene
Cluster—To determine whether the C. jejuniOAP gene homo-
logs were involved in OAP, PGO-acetylation levels were deter-
mined for themutants of the three putativeOAP genes (patA,
patB, andape1) and for themutant lacking the entire cluster
(oap) (Fig. 1C). PG was isolated from strains using an estab-
lished protocol that minimizes spontaneous O-linked acetate
hydrolysis and was assessed for OAP levels by quantifying
released acetate and MurNAc (49, 50).
The O-acetylation level for the wild-type strain 81-176 was
determined to be 12.5  0.71% relative to MurNAc content.
O-Acetylation levels among the mutants varied according to
their predicted function (Table 1). Deletion of patA and patB
resulted in a reduction inO-acetylation levels at 2.45 0.14 and
3.05  0.22% relative to MurNAc content, respectively. Dele-
tion of the entire gene cluster in oap resulted in a decrease in
O-acetylation levels to 2.10  0.18%, similar to that of patA
andpatB. Previous studies using Escherichia coli (which lacks
PG O-acetyl groups) showed undetectable levels of acetate
using identical methods (50, 51). This suggests that patA/B
contributes to PGO-acetylation inC. jejuni, but their absence is
insufficient to abolish OAP. Deletion of ape1 led to an increase
inO-acetylation to 35.6 2.25% relative to total MurNAc con-
tent. These results are in accordance with the functions
described for homologs in N. gonorrhoeae and N. meningitidis
(30, 42–44).O-Acetylation levelswere restored towild-type levels
in the ape1 complement (11.78  0.52%). Analysis of the
O-acetylation levels forpatA andpatB complements were not
performed as, unlike the ape1 mutant, phenotypic differences
between these mutants,oap and wild type, were in almost every
case not statistically significant or were minimal (see below).
C. jejuni OAPMutants Exhibit Altered PGMuropeptide Pro-
files, with ape1 Displaying the Most Dramatic Changes from
Wild Type—O-Acetylation has been described as a PGmatura-
tion event occurring after transglycosylation and transpeptida-
tion (30). Cleavage of PG by bacterial LTs is inhibited by PG
O-acetylation. Thus,O-acetylation may impact PG maturation
Cjj_0636ftnpatApatBape1OM effluxmacB
Cjj_0636ftnpatApatBOM efflux KmR
OM efflux KmR ftn Cjj_0636
Cjj_0636ftnpatApatBape1OM efflux KmR
Cjj_0636ftnpatBape1OM efflux KmR
CmR ape1
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FIGURE 1. Location ofO-acetyl groups on peptidoglycan subunits, organization of the C. jejuniOAPgene cluster, and description of deletionmutant
and complement construction.A, structures of the disaccharidemuropeptides showing non-O-acetylated PG andO-acetylated PG, location ofO-acetylation
(arrow), and the putative involvement of the oap genes. B, genomic organization of the C. jejuni OAP gene cluster in the 81-176 wild-type strain (gray).
cjj81176_0638, cjj81176_0639, and cjj81176_0640 are the C. jejuni homologs of ape1, patB, and patA respectively, as identified by BLAST using the N. gon-
orrhoeae OAP genes sequences. C, OAP mutants were generated by homologous recombination with a mutated copy of the gene (or the entire cluster for
oap) inwhich a portion of the gene (or cluster) was deleted and replacedwith a non-polar KmR cassette (aphA3) (47). Resistance to Kmwas used as a selective
marker for successful homologous recombination inC. jejuniwith themutatedgene.D, complement construction (withape1usedas anexample, designated
ape1C). EachOAPgeneplus upstream sequence containing the ribosomal binding sitewas cloned into the pRRC vector that contains homologous regions to
three ribosomal intergenic regionsdownstreamof theCmRcassette for selectionof successfulC. jejuni transformants. Complement constructswere transformed into
their respectivemutant backgrounds.MacB, macrolide-specific efflux pump;OMefflux, outermembrane efflux; ftn, ferritin; 23S, 23S ribosomal RNA (48).
TABLE 1
O-Acetylation levels of C. jejuni 81-176, ape1, ape1C (comple-
mentedape1),patB,patA,andoap (amutant inwhich theentire
cluster was deleted: ape1, patB, and patA), as determined by base-
catalyzed hydrolysis and release of acetate reported as a%O-acetyla-
tion relative to MurNAc content
Strain % O-acetylationa (mean S.D.)
81-176 12.5 0.71
ape1 35.6 2.25
ape1C 11.8 0.52
patB 3.05 0.22
patA 2.45 0.14
oap 2.10 0.18
a Results shown are of one representative biological replicate measured in tripli-
cate S.D.
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events in C. jejuni, affecting aspects such as muropeptide pro-
files and glycan chain length (52). To investigate this, PG was
isolated from wild type and each of the mutant and comple-
mented strains, and the muropeptide composition was deter-
mined. HPLCs are shown in Fig. 2. Raw data (relative abun-
dance of each muropeptide) and summarized muropeptide
profiles can be found in Tables 2 and 3, respectively.
Themethod used formuropeptide analysis results in the loss
of some of the PG O-acetyl groups (due to the alkaline condi-
tions for NaBH4 reduction resulting in base-catalyzed hydroly-
sis of theO-linked acetate) and is thus less precise at determin-
ing O-acetylation levels than the methodology used above.
Nonetheless, similar trends were observed, further supporting
gene product function. PGO-acetylation levels were reduced in
patA, patB, and oap and increased in ape1 relative to
wild-type 81-176. Monomeric O-acetylated tetrapeptide spe-
cies andO-acetylated tetra-tetra dimeric species were absent in
patB, patA, and oap. The abundance of all detectable
O-acetylated muropeptide species was increased in ape1.
ape1 exhibited a large decrease in total anhMP species and
an increased average glycan chain length compared with wild
type, similar to observations made in N. meningitidis (33), and
is consistent with the observed O-acetylation levels, as de-O-
acetylation must precede LT activity. Conversely, in the
absence of patA or patB, the relative abundance of anhMP spe-
cies did not vary strongly from wild type.
Changes were also observed in other muropeptide species
between wild type and patA, patB, oap, and ape1. The
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muropeptides were reduced with sodium borohydride and separated on a Prontosil 120-3-C18 AQ reverse-phase column. HPLC profiles are shown for
wild-type strain 81-176 (A and E), ape1 (B), patB (C), patA (D), ape1C (F), and oap (G). Muropeptide profiles were generated in two sets of experiments
indicated by (1) for Sample Set 1 and (2) for Sample Set 2. The muropeptide structure represented by each peak was determined previously by mass
spectroscopy (18), and proposedmuropeptide structures of each peak corresponding to the peak number in the chromatogramare shown inH. The summary
of the muropeptide composition is shown in Table 3. G, N-acetylglucosamine; M, reduced N-acetylmuramic acid; L-Ala, L-alanine; D-iGlu, D-isoglutamic acid;
meso-Dap, meso-diaminopimelic acid; D-Ala, D-alanine Ac, O-acetyl groups at MurNAc C6 position; Anh, 1,6-anhydro group of MurNAc; *, it is not known on
which MurNAc residue the modification occurs.
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patA mutant showed an increase in monomeric tripeptides,
tetra-penta dipeptides, and tetra-tetra-tri tripeptides. For
patB, themonomeric tripeptides and dimeric tetra-penta spe-
cies increased relative to wild type.oap exhibited some differ-
ences from wild type that followed the same trend as with
patA, an increase in tetra-penta dipeptides and tetra-tetra-tri
tripeptides, and some that were unique to oap, an increase in
dipeptides and a decrease in tripeptides. Analyses of PGmuro-
peptide profiles for patA- and patB-complemented strains
patAC and patBC showed minimal changes from wild type
TABLE 2
Muropeptide composition of C. jejuniwild-type 81-176,ape1, patB, andpatA,ape1C,patBC,patAC, andoap showing relative abun-
dance of muropeptides corresponding to peaks in HPLCs (Fig. 2)
Peaksa Muropeptide
Sample Set #1 Sample Set #2
81-176 ape1 patB patA 81-176 ape1C patBC patAC oap
1 Tri 5.8 12.3 7.3 9.5 8.8 9.6 8.8 6.0 6.2
b Tetra-Gly-4 0.4 0.4 0.4 0.3 0.4
2 Tetra 16.1 16.6 15.8 15.2 16.1 16.9 16.2 15.7 15.1
3 Penta-Gly-5 0.6 0.8 0.7 0.7 0.8 1.0 1.2 0.9 1.0
4 Di 16.3 8.3 16.1 14.3 13.0 10.1 10.4 16.2 15.7
5 Tri-Ac 0.3 2.8 0.3 0.3 1.0 1.2 0.7 0.5 0.4
6 Tetra-Ac 0.6 2.6 0.0 0.0 0.6 0.7 0.5 0.0 0.0
7 Di-Ac 0.0 1.9 0.0 0.0 0.2 0.5 0.5 0.6 0.4
8 TetraTri 9.7 7.6 11.1 13.7 10.5 10.1 10.6 11.5 11.2
9 TetraPenta-Gly-5 0.4 0.7 0.6 1.0 0.8 0.9 1.0 0.8 1.2
10 TetraTetra 19.0 17.0 18.0 21.2 21.4 22.4 23.0 22.4 22.5
11 TetraPenta 0.0 0.1 0.0 0.0
12 TetraTri-Ac 1.8 3.4 1.6 0.0 1.5 1.7 0.9 0.0 0.0
13 TetraTetraTri 0.8 0.5 0.9 1.5 1.0 0.9 1.3 1.3 1.4
14 TetraTetra-Ac 0.3 1.1 0.0 0.0 1.7 1.8 1.4 0.4 0.0
15 TetraTetraTetra 2.9 7.0 1.9 2.8 2.5 2.8 3.1 2.9 3.4
16 TetraTriAnh I 1.2 0.5 1.3 1.3 1.1 1.0 1.1 1.3 1.2
17 TetraTriAnh II 2.6 1.6 2.5 2.7 2.4 2.1 2.2 2.5 2.5
18 TetraTetraAnh I 3.0 1.8 2.8 2.7 2.8 2.8 3.0 3.1 3.0
19 TetraTetraAnh II 5.6 3.7 4.9 4.9 5.2 5.0 5.1 5.4 5.5
b TetraTetraTriAnh 1.1 0.9 1.3 1.4 1.7
20 TetraTetraTetraAnh 4.3 1.9 3.9 4.3 4.1 4.2 4.9 4.5 5.3
1–20 All knownc 91.2 92.3 89.5 95.9 96.8 97.1 97.4 97.7 97.9
a Peak numbers correspond to those from HPLCs in Fig. 2. Muropeptides are named according to Glauner et al. (88) and are depicted in Fig. 2H. Di, disaccharide dipeptide
(disaccharide 1,4-linked N-acetylglucosamine-N-acetylmuramic acid); Tri, disaccharide tripeptide; Tetra, disaccharide tetrapeptide; Penta, disaccharide pentapeptide
Muropeptides 1–7 are monomeric, and muropeptides 8–20 are dimers and trimers connected by peptide cross-links. Modifications: Gly, glycine in position 5 of a peptide
side chain; Ac, O-acetyl groups at the C-6 hydroxyl group of MurNAc; Anh, 1,6-anhydro-N-acetylmuramic acid.
b Peak was previously unidentified in Sample Set #1.
c The total abundance does not add up to 100% due to the presence of peaks for which a structure has not been assigned.
TABLE 3
Summary of PGmuropeptide composition for C. jejuni 81-176,ape1,patB,patA,ape1C,patBC,patAC, andoap
Muropeptide species
Percentage of peak areaa
Sample Set #1 Sample Set #2
81-176 ape1 patB patA 81-176 ape1C patBC patAC oap
Monomers (total) 43.5 49.1 44.9 41.7 42.2 41.5 39.6 41.2 40.0
Dipeptide 17.8 11.0* 18.0 15.0 13.6 11.0 11.2 17.2 16.4
Tripeptide 6.7 16.4* 8.5 10.2* 10.1 11.1 9.7 6.6* 6.7*
Tetrapeptide 18.3 20.9 17.6 15.8 17.2 18.1 17.1 16.1 15.5
Pentapeptides-Gly 0.6 0.9* 0.7 0.7 0.8 1.0 1.3* 0.9 1.0
O-Acetylated 1.0 8.0* 0.3* 0.3* 1.9 2.4 1.7 1.1* 0.8*
Dimers (total) 47.7 40.7 47.6 49.4 48.8 49.4 49.5 48.5 48.1
TetraTri 16.8 14.2 18.4 18.5 16.0 15.5 15.2 15.7 15.2
TetraTetra 30.5 25.6 28.6 29.9 32.0 33.0 33.2 32.0 31.7
TetraPentaGly 0.4 0.9* 0.6* 1.0* 0.8 0.9 1.1* 0.8 1.2*
Anhydro-Dimers 13.5 8.2* 12.7 12.1 11.8 11.3 11.6 12.6 12.4
O-Acetylated 2.2 4.9* 1.7 0* 3.2 3.7 2.3 0.4* 0*
Trimers (total) 8.8 10.2 7.5 8.8 7.8 8.1 9.5 8.9 10.2*
TetraTetraTri 0.9 0.5* 1.0 1.5* 1.0 0.9 1.3* 1.3* 1.4*
TetraTetraTetra 8.0 9.7 6.5 7.3 6.8 7.2 8.2 7.6 8.8
Dipeptides (total) 17.8 11.0* 18.0 15.0 13.6 11.0 11.2 17.2 16.4
Tripeptides (total) 15.4 23.6* 18.0 19.9 18.4 19.1 17.7 14.9 14.7
Tetrapeptides (total) 65.9 64.0 62.9 63.9 65.1 67.1 67.6 64.8 65.1
Pentapeptides (total) 0.8 1.3* 1.0 1.2* 1.2 1.5 1.9 1.3 1.6*
O-Acetylated (total) 2.1 10.4* 1.2* 0.3* 3.5 4.3 2.9 1.3* 0.8*
Anhydromuropeptides 8.3 4.8* 7.8 7.5 7.7 7.4 7.9 8.3 8.6
Average chain length 12.0 20.8* 12.8 13.3 13.0 13.5 12.6 12.0 11.6
Degree of cross-linkage 29.7 27.2 28.8 30.6 29.6 30.1 31.1 30.2 30.9
% peptide cross-links 56.5 50.9 55.1 58.3 57.8 58.5 60.4 58.8 60.0
a Values represent the percentage area of each muropeptide from raw data (found in Table 2) calculated to give a total of 100%. Boldface numbers represent a change in rela-
tive abundance of20% from wild type. Boldface numbers with an asterisk represent30% change from wild type. Percentages shown are calculated from values rounded
to the nearest 0.1%. Muropeptide profiles were generated in two sets of experiments, Sample Set #1 and Sample Set #2. Muropeptide profiles were compared with the wild-
type 81-176 muropeptide profile that was analyzed in the same sample set.
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with restored O-acetylation levels for patBC but not patAC.
The largest number of changes and greatest degree of change
occurred in ape1. In ape1, total dipeptide species decreased
and total tripeptides and pentapeptides increased relative to
wild type. The total amount of dimers also appeared to be
slightly lower in ape1. The majority of the muropeptide
changeswas restored to nearwild-type levels in theape1 com-
plement strain (ape1C).
Recombinant Ape1 Has in Vitro Acetylesterase Activity on
p-Nitrophenyl Acetate and O-Acetylated PG—Based on the
muropeptide data observed for ape1 and phenotypic data
shown below, the acetylesterase activity of Ape1was confirmed
biochemically. Ape1 was expressed with a His6 tag and minus
the signal peptide at either the N or C terminus and purified
(Fig. 3, A and B). Both recombinant proteins purified well (Fig.
3C), producing 3 ml of 0.9–1.2 mg/ml protein after dialysis
from a starting culture of 100 ml. The expected sizes of the
recombinant proteins are 45.0 and 44.9 kDa for His6-Ape1 and
Ape1-His6, respectively. The specific activity of purified Ape1
was determined using p-nitrophenylacetate (pNPAc), a com-
mon substrate used to test esterase activity (31, 32). Specific
activity for Ape1-His6 ranged between 26.1 and 38.9 mol/
min/mg of protein (Fig. 3D), which was higher than the
reported specific activity of10.4 mol/min/mg for N. gonor-
rhoeae Ape1 measured under similar reaction conditions (32).
This demonstrates that the recombinant protein exhibits acety-
lesterase activity. His6-Ape1 showed similar specific activity
with pNPAc (data not shown).
Ape1-His6 was also assayed for acetylesterase activity on its
native substrate (Fig. 3E), O-acetylated PG. PG isolated from
ape1 was used as the substrate due to the increased PG
O-acetylation levels in this strain. Cleavage of O-acetyl groups
was assessed using a commercial acetic acid assay kit (Mega-
zyme) as an end point experiment. At 0 h, the average acetate
concentration in the sample was 2.4 0.3g/ml. Incubation of
ape1 PG for 24 h in the absence of enzyme resulted in an
average acetate concentration of 3.1 0.1 g/ml, and an aver-
age acetate concentration of 35.9 0.7 g/ml after incubation
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FIGURE 3.A, SignalP 4. 1 server (83) output for signal peptide prediction of in-frame translation of Cjj-81-176_0638. C-score (the predicted first amino acid of the
mature protein), S-score (the likelihood that a particular amino acid is part of a signal peptide), and Y-score (amino acid with a high C-score exhibiting
the greatest change in the S-score) predicted the cleavage site to be between the 21st and 22nd amino acids. B, Cjj81-176_0638was cloned in-frame without
the signal peptide into pET28a() protein expression vectors. Top, map of cloning sites in pET28a() commercial expression vector. Middle, Ape1-His6
expression construct. NcoI and EcoRI were used to produce a C-terminal His6-tagged Ape1 protein that uses ATG start codon and TGA stop codon encoded in
the vector. Bottom, His6-Ape1 expression construct. NheI and EcoRI were used to produce an N-terminal His6-tagged protein that uses AUG start codon
encodedby the vector and theoriginal stop codon fromCjj81-176_0638. rbs, ribosome-binding site; LVPRG, thrombin cleavage site;MCS,multiple cloning sites.
Gene organization not to scale.C,His6-taggedApe1 after nickel-nitrilotriacetic acid-agarose purification shows protein of the predicted size (45.0 and 44.9 kDa
for His6-Ape1 and Ape1-His6 respectively) in eluted fractions after SDS-PAGE analysis. D, purified Ape1-His6 exhibits acetylesterase/deacetylase activity using
pNPAc as a substrate (45). Reactions were monitored over 5 min as a change in the absorbance at 405 nm (formation of p-nitrophenol) after cleavage of the
acetyl group. No enzyme control and BSA control are overlapping and show no acetylesterase activity. Results shown are from one protein purification
experiment. Results are reproducible for each expression andpurification experiment, and activitywas routinely assessedbefore performing enzymatic assays
on PG. E, Ape1-His6 has acetylesterase activity using PGmuropeptides as a substrate. Determination of acetic acid concentration after treatment ofape1 PG
withApe1-His6 for 24 hwas performedusingMegazymeacetic acid assay kit. Treatment andno enzyme controlwere comparedwith acetic acid concentration
at 0hof treatment using Student’s t testwith * and **** indicatingp values of0.05 and0.0001, respectively. Results are fromone representative experiment
of two biological replicates performed in triplicate.
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with Ape1-His6. Because of the insoluble nature of PG, data
from this assay cannot be expressed in the classical definitions
of enzyme kinetics using the native substrate.
Microscopy and CellTool Analyses of C. jejuniape1 Popula-
tionMorphology Reveal Shape Pleomorphism—Because a num-
ber of changes were observed in themuropeptide profiles of the
OAP mutants, it was hypothesized that these changes may
result in changes in cell shape. The morphology was examined
by DICM after 4 and 7 h of growth initiated at anA600 of 0.05 to
obtain early- and mid-exponential phase cultures (Fig. 4).
Whereas wild type exhibited the classicalC. jejuni helical shape
(Fig. 4A), ape1 exhibited primarily “comma-shaped” and dif-
ferentially curved cells (Fig. 4B). Wild-type helical morphology
was restored upon complementation (Fig. 4C). A distinct
change in morphology was not observed for the other OAP
mutant populations (Fig. 4, D–F).
The open-source shape analysis program CellTool (53) was
used to quantify the changes in shape in the OAPmutants (Fig.
5). The program contains a set of tools used to extract shapes
frombinary images that can then be used to assess and compare
the population morphology using a variety of metrics. Ex-
tracted shapes from the wild-type population were aligned to
one another, and principal component analysis (PCA) was per-
formed to generate a baseline model for variation within the
wild-type population. At mid-exponential phase, three shape
modes (principal components that define specific changes in
cell shape in the population) described 95% of the morpholog-
ical variation in the C. jejuni wild-type population. Each shape
mode represented an observable metric (Fig. 5,A and B). Shape
mode 1 corresponded to variation in cell length, explaining
90% of the variance (as expected because a population likely
exhibits asynchronous growth and division). Shape mode 2
explained 1.9% of the variance and appeared to have some rela-
tion to the curvature and wavelength of the cell. A third shape
mode explained 1.7% of the variance and described differences
in cell width. Contours ofmutantswere aligned to thewild-type
shape model as a reference and Kolmogorov-Smirnov (KS) sta-
tistical tests were used to compare sample probability distribu-
tions. Based on the large population of bacterial cells assessed
and conditions required forKS analysis, ap value of 0.00001was
used as a cutoff for significance (Fig. 5B) (54).
No strains were significantly different from the wild type in
shape mode 1 (cell length) or from each other, with the graph-
ical output also showing that the population distributions over-
lay very closely. In shape mode 2 (cell curvature), some differ-
ences in population distribution between wild type and ape1C,
patA, patB, and oap were significant by the KS cutoff uti-
lized. However, the graphical output showed that these strains
were similar to wild type, whereas ape1 exhibited a dramatic
shift in the population distribution maximum (2.2 standard
deviations from thewild-typemean). Shapemode 3 (cell width)
was significantly different in all strains comparedwithwild type
(with the exception of ape1C), and each exhibited a shift of
approximately 1 S.D. in the population maximum toward a
reduced width compared with the wild-type mean as
reflected in the graphical output. A 2D scatterplot of mea-
surements of each individual contour of wild type, ape1,
and ape1C populations for shape modes 2 and 3 (Fig. 5C)
likewise shows that there was a clear difference in shape for
the ape1 population compared with wild type and ape1C.
Early-exponential phase bacteria exhibited similar popula-
tion shifts as for mid-exponential phase bacteria (with the
exception of shape mode 3, as cell width was not captured as
a major contributor to the variance in shape for wild type at
this time point). The most notable shift at early-exponential
phase was observed for cell curvature (shape mode 2) in
ape1 (data not shown).
Phenotypic Analyses Reveal the Importance of O-Acetylpepti-
doglycan Esterase Activity on Various Aspects of C. jejuni
Physiology—TheOAPmutants were assessed for different phe-
notypes serving as indicators of transmission and/or coloniza-
tion efficiency: motility in soft agar, biofilm formation, hydro-
phobicity, and sensitivity to a variety of inhibitory compounds.
Motility is a major colonization determinant for C. jejuni
(55). Although all strains exhibited defective halo formation
compared with wild type in soft agar plates after point inocula-
tion (Fig. 6A), the halo diameter of ape1was 70% of wild type,
whereaspatB,patA, andoapwere only modestly defective
at 90, 90, and 87% of wild type. Complementation of ape1
restored the halo formation of the mutant to 90% of wild type
and was significantly different from that of ape1. In addition,
ape1 formed aberrant halos on soft agar with rough perime-
ters as opposed to the circular halos formed by wild type. This
halo phenotype was absent in the other mutants tested and was
rescued by complementation.
The ability to form biofilms is important in C. jejuni persis-
tence and transmission. C. jejuni has been shown to survive
up to 28 days in a biofilm state and is a general stress response
(56). The ability of our OAP mutants to form biofilms was
assessed in borosilicate test tubes by crystal violet staining of
standing cultures (57). The ape1 mutant exhibited a hyper-
biofilm phenotype, producing 5.5-fold more biofilm than wild
type (Fig. 6B).ape1 also developed flocs of bacteria suspended
in the broth (58), which were not observed for wild type nor
included in the crystal violet quantification of surface-adhered
biofilm (data not shown). Complementation of ape1 restored
biofilm formation to wild-type levels (Fig. 6B). Biofilms formed
FIGURE4.C. jejuniape1mutanthas apleomorphic cell shape, andother
OAPmutants display unaltered cell morphology.DICM showing themor-
phology of wild-type strain C. jejuni 81-176 (A), the differentially curved
ape1strain (B), the complemented strainape1Cwith restoredmorphology
(C),patB (D),patA (E), andoap (F). Cellswereharvested from7hofgrowth
in MH-TV broth at a mid-exponential phase of growth. Scale is 2 m (black
bar).
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bypatB andpatAwere indistinguishable fromwild type, but
oap produced 2.5-fold more biofilm than wild type. Char-
acterization of ape1 biofilms by microscopy was unsuccessful
asape1 formed biofilms poorly on coverslips unlike wild type.
This indicates altered cell surface properties inape1. Cell sur-
face hydrophobicity was assessed with hexadecane partitioning
(Fig. 6C) (59). The percent hydrophobicity ofape1was signif-
icantly higher (2.0-fold) than wild type and was restored to
wild-type levels upon complementation.
The sensitivity of the OAP mutants to detergents, salts, and
antimicrobial compounds was tested by determining the mini-
mum inhibitory concentration that reduces growth by 50%
relative to a control as measured by A600 (MIC50) (Table 4).
Only ape1 exhibited an increased susceptibility to any of
the compounds tested as follows: the amphipathic bile salt
sodium deoxycholate (DOC) and MgCl2. For ape1, an
MIC50 range for DOC of 0.16 to 0.31 mg/ml was observed,
whereas the MIC50 for wild type was greater than the highest
concentration of DOC tested (10 mg/ml). ape1 exhibited
a 4–8-fold reduction in MIC50 for MgCl2 compared with
wild type. Complementation of ape1 restored wild type
sensitivity profiles.
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FIGURE 5. CellTool analysis of wild-type strain 81-176, ape1, ape1C, patB, patA, and oap population morphology. Differential interference
contrast images were taken of strains grown for 7 h in MH-TV broth at a starting A600 of 0.05 (to mid-exponential phase). Images were converted to binary
format (white cells on a black background), and lumps and artifacts were manually removed before processing with CellTool “extract contours function” to
generate contours representing each cell (53). A, contour extraction, alignment, and generation of the PCA shape model for C. jejuniwild-type strain 81-176.
CellTool “align contours” function was used to align the contours of the wild-type population to one another. B, PCA was performed to generate a wild-type
shape model that explains 95% variation in the population in principal components called “shape modes.” Shape modes 1, 2, and 3 represent variation in
length, curvature/wavelength, and width, respectively. The extracted contours of the mutant populations were then aligned to the wild-type shape
model, and a measurement representing the normalized standard deviation from the wild-type mean in each shapemode was generated and depicted
graphically. KS tests were performed for each shapemode between each population and are summarized below the plots. C,measurements of wild type,
ape1, and ape1C were plotted with shape mode 2 along the x axis and shape mode 3 along the y axis to create a scatterplot showing the variation in
the different populations.
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Ape1 Is Required for C. jejuni Bacteria-Host Interactions—
The contribution of OAP to C. jejuni host interactions was
examined by determining recovery of the mutants after
chick colonization and host cell infections, as well as the
ability to elicit IL-8 secretion in vitro in human epithelial
infections.
Chickens are an avian reservoir for C. jejuni and a com-
mon source of human infection. The ape1 mutant exhib-
ited a significant 4.4-log decrease in colonization (Fig. 7A),
whereas patB, patA, and oap mutants were not defec-
tive for chick colonization. The defects in long term survival
in broth for the OAP-deficient mutants were modest com-
pared with ape1, so the defect in chick colonization could
be related to the altered long term survival properties of
ape1.
The ability of a C. jejuni strain to invade and survive in non-
phagocytic epithelial cell lines has been shown to correlate with
virulence (11, 60, 61). The ability of the C. jejuniOAPmutants to
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24 h of strains point-inoculated in 0.4% semi-solid agar. Representative images of halos are shown below each graph. Results shown are representative
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TABLE 4
MIC50 of C. jejuni OAPmutants determined by broth dilution
Measurements indicated with a “-” have not been tested. Measurements in boldface were consistently 4-fold different from wild type over three experiments. MIC50,
minimum inhibitory concentration to reduce growth by 50% as assessed by optical density.
Compound
MIC50
81–176 ape1 patB patA oap ape1C
Detergents
Deoxycholate (mg/ml) 10 0.16–0.31 5-10 1.3-10 1.3-10 1.3-10
SDS (mg/ml) 10–12.5 2.5–6.25 10–12.5 2.5–12.5 5–6.25 12.5
Triton (% v/v) 0.05 0.02–0.005 0.02–0.05 0.02–0.05 0.05 0.05
Antimicrobials
Ampicillin (g/ml) 2.4–4.9 1.2–4.9 4.9 4.9 2.4–4.9 2.4
Lysozyme (mg/ml) 5 5 5 5 5 5
Polymyxin B (g/ml) 20 10 10 10 10 10–20
Protamine (g/ml) 31.3 15.6–31.3 31.3–62.5
Chelating agent
EDTA (M) 78–156 1.2–156 156 156 156 156
Salts
NaCl (mM) 62.5–250 31.3–62.5 62.5–125 125 62.5–125 62.5–125
MgCl2 (mM) 62.5–125 15.6 62.5–125 62.5–125 62.5–125 62.5–125
CaCl2 (mM) 125 125–250 125–250 125–500 500 125
KCl (mM) 62.5 31.3–62.5 62.5 31.3–62.5 125 31.3–62.5
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adhere to, invade, and survive inside the human epithelial cell line
INT407 was assessed by a gentamicin (Gm) protection assay.
Recovery of ape1 was significantly reduced at the adherence,
invasion, and intracellular survival timepoints in comparisonwith
wild type (Fig. 7B). ape1C, patB, patA, and oap displayed
wild-type INT407 infection profiles (Fig. 7,C–F).
As ape1was the only OAPmutant to demonstrate reduced
invasion of the INT407 cells, its ability to elicit IL-8 secretion
from INT407 cells was assessed by ELISA. Cells infected with
ape1 reproducibly exhibited statistically significant lower levels
(60–79%) of IL-8 secretion comparedwith cells infectedwithwild
type (Fig. 7G).ape1Cdidnot complement IL-8 inductiondefects.
Discussion
PG plays roles in multiple facets of bacterial physiology. PG
modifications have been shown to influence pathogenic prop-
erties in several bacterial species (15, 20, 36). Here, the OAP
genes in C. jejuni were shown to contribute to PG O-acetyla-
tion/de-O-acetylation, consistent with their predicted func-
tions. These genes were also important for several key physio-
logical and pathogenic properties. This was most notable for
ape1, which was involved in PG de-O-acetylation and the only
OAPgene significantly required for every phenotype examined.
Deletion of patA or patB, which act toO-acetylate MurNAc,
was non-lethal as found in several other bacterial species (33,
37, 44). This suggests that O-acetyl groups added by PatA/B
play a non-essential role for growth of C. jejuni in the labora-
tory. Unlike in N. meningitidis where OAP is exclusively medi-
ated by patA/B (33), the O-acetylation levels were not reduced
to 0% in C. jejuni, indicating the presence of alternative PG
O-acetylation machinery or compensation by alternative
mechanisms, as was observed with E. coli WecH that acted as
an acetate transporter (62). Expression of N. gonorrhoeae PatB
in E. coli increased OAP levels from 0.05 to 1%, which was
detrimental to the cells (62). The effect of low levels of OAP on
E. coli biology provides support that the residual O-acetylation
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in C. jejuni may be sufficient to mask mutant phenotypes in
patA/B/oap that would otherwise be observed if PGO-acety-
lation were completely absent. There are conflicting results for
the essentiality of ape1 in N. gonorrhoeae (43, 44). In C. jejuni,
ape1 was not essential. Deletion of ape1 resulted in increased
O-acetylation levels almost triple that of wild type, supporting
the role of Ape1 in C. jejuni PG de-O-acetylation. Ape1 acety-
lesterase activity was also confirmed in vitro using the artificial
substrate pNPAc as well as its natural substrate, O-acetylated
PG from ape1.
It should be noted that the OAP levels of wild-type C. jejuni
81-176 described here were lower than those reported in a pre-
vious study for ATCC 700819 andNCTC 11168 (42). However,
the strains and growth conditions used differed between the
studies. A direct comparison of how these and other potential
factors might affect C. jejuni PGO-acetylation has not yet been
assessed but will be the topic of future work.
As with the OAP analyses described above, the muropeptide
profiles also showed differences in PG O-acetylation levels for
the C. jejuni OAP mutants. Although these data are not truly
quantitative for O-acetylation, they offer additional qualitative
support for the role of these OAP genes in PG O-acetylation.
N. meningitidisape1 showed an increase in onlyO-acetylated
muropeptides with a tri-peptide stem in comparison with wild
type (33), although the muropeptide analysis ofC. jejuniape1
suggests that Ape1 in C. jejunimay be regulated differently, as
this specificity was not observed. Previous observations with
N. gonorrhoeae PatB O-acetyltransferase using in vitro assays
showed specificity of PatB toward O-acetylation of tetrapeptides
(30). Adecrease inO-acetylated tetrapeptide specieswas observed
for theC. jejunipatA andpatBmutants (Table 2); however, as
this could have beendue to hydrolysis during the preparation pro-
cedure, further biochemical analysis will be required.
As expected, ape1 also exhibited a 42.1% decrease in rela-
tive anhMP levels (presumably due to impaired LT activity) and
a greater average chain length. Although chain length was not
directly measured, these data support previous findings that
Ape1 regulates PG chain length as in N. meningitidis (33). The
anhMP levels changed only marginally in patA, patB, and
oap supporting a putative compensation ofO-acetylation by a
yet unknown mechanism consistent with our OAP analyses
and/or O-acetylation itself may not be an essential or the only
controlmechanism for LT activity inC. jejuni. LTs inE. coli and
Pseudomonas aeruginosa have been found in complexes with
peripheral membrane-bound lipoproteins and PBPs and are
thought to be controlled spatially as well as coupled with syn-
thesis to prevent autolysis (52, 63–65). For C. jejuni, the obser-
vations here do suggest a role for OAP in regulating LT activity,
but other control mechanisms likely exist.
Differences in the muropeptide composition could be possi-
ble if O-acetyl groups influence substrate recognition by PG
remodeling enzymes. Care must be taken in interpreting how
differences in relative abundance actually affect overall PG
composition. For instance, small changes in muropeptides of
low abundance can result in changes 20% (i.e. total penta-
Gly-5 species, whichwere 0.8% inwild type and 1.3% forape1;
Table 3). Conversely, larger changes in muropeptides of high
abundance can produce changes20% yet may still be consid-
ered significant. For example, dimeric species constituted
47.7% of themuropeptides inwild type and 40.7% inape1; this
degree of changemay bemeaningful, as it affects 7% of the total
muropeptides, is unique compared with other mutants tested,
and would be considered significant using the 10% cutoff
described for H. pylori (27). Regardless, it is clear that the
absence of ape1 affects the PG muropeptide profile more so
than the absence of patA/B (Table 3 and Fig. 2). These changes
could be a result of increased O-acetylation affecting substrate
recognition by PG remodeling enzymes or missing protein-
protein interactions in the absence of Ape1 and will require
more extensive analysis in later studies.
N. meningitidis Ape1 showed preference for O-acetylated
tripeptide substrates in vivo (33), asmentioned above. The crys-
tal structure for N. meningitidis Ape1 has recently been solved
(46), confirming its classification as a member of the Ser-Gly-
Asn-His (SGNH) hydrolase superfamily based on active site
catalytic residues (32). These residues are also conserved in
C. jejuni Ape1. The putative PG binding domain in the N-ter-
minal lobe of N. meningitidis Ape1 and its interaction with PG
have yet to be described (46). As N. meningitidis Ape1 was
active against variousO-acetylatedmuropeptides in vitro, spec-
ificity may be due to regulation of activity through unknown
interaction partners. The putative PG binding domain at the N
terminus may confer substrate specificity (33). There is only
26/42% amino acid sequence identity/similarity between the
N-terminal domains of N. meningitidis Ape1 and C. jejuni
Ape1, so the two enzymes may possess different regulatory
regions. Another possibility is that C. jejuni lacks the Ape1
interaction partners present in N. meningitidis conferring sub-
strate specificity.
One of C. jejuni’s defining characteristics is its helical shape,
a trait defined by the cytoskeleton-like components that coor-
dinate the PG biosynthetic machinery (66). The muropeptide
composition was altered in C. jejuni/H. pylori periplasmic PG
hydrolase mutants, i.e. pgp1/csd4 and pgp2/csd6, and
exhibited a straight rod versus helical morphology (18, 19, 28,
67). Deletion ofC. jejuni ape1 also resulted in alteredmuropep-
tide composition and shape, but the change in shape was not as
dramatic as in the abovementioned straight-rodmutants. Thus,
CellTool was employed for shape quantification. This analysis
showed that ape1 was significantly different from the wild-
type population in curvature in that it had both an average
shape with a larger wavelength compared with wild type and a
greater variance of curvature within the population. Ape1 was
shown to affect cell size in N. meningitidis (33). In this study,
there was a significant increase in total area of ape1 cells when
compared with wild type at early-exponential phase but not at
mid-exponential phase (data not shown). One explanation could
be that Ape1 activity varies at different growth stages inC. jejuni.
Multiprotein flagellar complexes span the PG layer with
some proteins of the complex proposed to directly interact with
PG. These proteins include FlgI, which makes up the P-ring of
the periplasmic rod-structure in the hook-basal body (55, 68,
69), and MotB in H. pylori that makes up part of the flagellar
stator responsible for generating torque (70). In Salmonella
enterica, the switch protein FliG of the C-ring, which acts as the
rotary component of the flagella, responds to chemotactic sig-
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nals and interacts withMotA of the stator that in turn interacts
with PG-boundMotB (71). In E. coli, CheY is the response reg-
ulator that interactswith FliG to alter rotational direction of the
flagella (72). Homologs of all these flagellar components are
found in C. jejuni (55).
In H. pylori, the loss of the membrane-bound LT, MltD,
affectedmotilitywithout affecting the localization or number of
flagella; this was hypothesized to result from the inability of
MotA/B to generate torque due to impaired PG-MotB interac-
tions (75). Similarly, the accumulation of O-acetylation in
ape1 and the subsequent effect on LT activity could affect
motility. An improperly assembled or unstable stator may
impair the ability of the flagella to alter rotational direction in
response to chemotactic signals. Mutants in C. jejuni cheY
appear completely immotile on soft agar but not bymicroscopy
(73, 74). Thus, the halo morphology does not support a com-
plete loss in the ability to alter rotational direction but may still
suggest an impaired response. The pgp1 and pgp2 straight
mutants were also defective for motility in soft agar, so the
changes in ape1 morphology could also account for the
observed defects.
Biofilm formation in C. jejuni requires flagellum-mediated
motility and attachment to a surface, lysis, and release of extra-
cellular DNA to form the biofilmmatrix (76).ape1was defec-
tive for motility in soft agar but was not immotile. Despite this,
ape1 exhibited a hyper- rather than hypo-biofilm formation
phenotype. Envelope stress was recently shown to be a trigger
for C. jejuni biofilm formation. A mutant exhibiting envelope
stress was hyper-biofilm, and with DOC at 0.5 mg/ml, C. jejuni
81-176 wild type also exhibited enhanced biofilm formation
(76). In this study, DOC concentrations below 0.5 mg/ml
inhibit growth of ape1 (MIC50; Table 4). This, together with
the hyper-biofilm phenotype and increased cell surface hydro-
phobicity, suggests that the accumulation of OAP results in
alteredmembrane properties andmay be contributing tomem-
brane stress inape1. However, becauseoap exhibited hyper-
biofilm formation as well and did not show evidence of mem-
brane stress (i.e. no change in surface hydrophobicity or DOC
sensitivity), the hyper-biofilm property may be partially inde-
pendent of Ape1 activity and could be due to the loss of the
Ape1 protein itself.
In E. coli, PG-associated lipoprotein (Pal) is often found in
PG-protein complexes that are proposed to maintain envelope
integrity. The phenotypes of some E. coli pal deletion mutants
share similarities to C. jejuni ape1, including increased sensi-
tivity to bile salts and signs of altered motility (77). In addition,
the PG binding domain of E. coliMotB and E. coli Pal are inter-
changeable (78) and both interact with MurNAc; our observa-
tions in ape1 could be a result of the presence of excess of
O-acetyl groups on the PGMurNAc residues preventing stabi-
lizing interactions betweenmultiprotein structures and the PG
sacculus.
Given the proposed role of O-acetylation in lysozyme resis-
tance, it was expected that C. jejuniOAP mutants would dem-
onstrate differential resistance to lysozyme.However, no differ-
ences were observed in lysozyme sensitivity (MIC50). Attempts
to destabilize the outer membrane by adding EDTA (at MIC50
and concentrations down to 4-fold less than MIC50) or lacto-
ferrin (at physiological concentration of 3 mg/ml, as described
previously (37)) to the lysozyme incubations also failed to result
in differential lysozyme sensitivity (data not shown). Lysozyme
turbidometric assays were also unsuccessful due to the low
yield of PG, resulting in an initial absorbance reading too low to
accurately detect a response (data not shown).
Chick colonization by ape1 was significantly impaired
compared with wild type and patA, patB, and oap colo-
nized to wild-type levels (Fig. 6A). Motility and chemotaxis are
important for colonization (79); thus, this could be a potential
explanation for the ape1 chick data. Alternatively, and/or
additionally, the altered morphology and PG structure (18, 19),
increased DOC susceptibility, differential long term survival
properties, and other as-yet unknown factors could also con-
tribute to the ape1 colonization defect.
Of theOAPmutants, onlyape1was impaired in adherence,
invasion, and intracellular survival in INT407 epithelial cells.
Whether these observations represent defects at each time point,
defects in adherence that in turn affect recovery at later time
points, or if ape1 is very rapidly killed upon invasion (as the 3-h
“adherence” time point will also reflect invaded bacteria) will
require further experimentation. Infection of human INT407 epi-
thelial cells by ape1 also led to a decrease in IL-8 secretion. This
may correlate with its reduced invasion properties.
Somewhat surprisingly, the reduction in PG O-acetylation
had no significant effects on colonization, host cell interactions,
or any other phenotype examined except for marginal
decreases in halo formation, suggesting that under these con-
ditions OAP by PatA and PatB offers no fitness advantage in
host survival, which is perplexing and leaves the role of PG
O-acetylation in C. jejuni yet to be determined. In contrast, the
increase in O-acetylated PG in ape1 was detrimental to
C. jejuni inmultiple aspects important for pathogenesis. Future
studies will focus on finding a direct link between PG O-acety-
lation and the observed changes in physiology, identifying other
potential mechanisms of PG O-acetylation and de-O-acetyla-
tion, and revealing the underlying cause(s) of the impaired host
interactions for ape1.
Experimental Procedures
Strains and Growth Conditions—A list of bacterial strains
and plasmids used in this study can be found in Table 5. Con-
struction of mutant and complemented strains is described in
supplemental text S1 using primers listed in supplemental
Table S1. C. jejuni strains, unless otherwise stated, were grown
in Mueller-Hinton (MH; Oxoid) broth or agar (1.7% w/v) sup-
plemented with vancomycin (10 g/ml) and trimethoprim (5
g/ml) and when appropriate kanamycin (Km; 50 g/ml) and
chloramphenicol (Cm; 25 g/ml). Standard laboratory condi-
tions for C. jejuni growth were 38 °C under microaerophilic
conditions (12%CO2, 6%O2, inN2) in a Sanyo tri-gas incubator
for MH agar or for standing MH broth cultures. For shaking
MH broth cultures (hereafter referred to as broth cultures),
C. jejuni were cultured in airtight jars using the Oxoid Campy-
Gen Atmosphere generation system with shaking at 200 rpm.
Experiments were performed using cultures initiated at A600
0.002 and grown in shaking broth for 16–18 h to reach expo-
nential phased. For plasmid construction and protein purifica-
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tion, E. coli (DH5- or BL21) strains were grown at 37 °C in
Luria-Bertani (LB; Sigma) broth or LB agar (7.5% w/v) supple-
mented with ampicillin (100g/ml), Km (25g/ml), or Cm (15
g/ml) as required.
PG Isolation and Assessment of O-Acetylation Levels—PG
isolation forO-acetylation analysis was performed as described
previously with minor modifications (32, 51). Each strain was
grown on 60 MH-T agar plates (supplemented with Km or
Cm as necessary) for18–20 h. The cells were harvested from
the plate with 1ml of ice-coldMH broth per plate and added to
a conical tube. Strains were assessed by DICM to examine for
contamination and the presence of coccoid cells, ensuring that
the cultures had not entered stationary phase. C. jejuni cells
transition from a helical to coccoid form in stationary phase.
The cells were collected by centrifugation, resuspended in 50
ml of 25 mM sodium phosphate buffer, pH 6.5, and boiled in an
equal volume of 8% w/v SDS in 25 mM sodium phosphate buff-
ered at pH6.5 for 3 h under reflux with stirring (final concen-
tration 4% SDSw/v). SDS-insoluble PGwas washed with sterile
double distilled H2O (methylene blue/chloroform tests were
performed to detect SDS) (80), frozen, and lyophilized. Lyoph-
ilized PG was resuspended in a minimal volume of buffer con-
taining 10mMTris-HCl, pH 6.5, and 10mMNaCl and sonicated
(Misonix XL 2020,Mandel Scientific) on ice with amicrotip for
2 min. The suspension was treated with 100 g/ml -amylase
(Fluka Biochemika), 10 g/ml DNase I (Invitrogen), 50 g/ml
RNase A (ThermoScientific), and 20 mM MgSO4 overnight at
37 °C. Protease (from Streptomyces griseus, Sigma), pre-incu-
bated at 60 °C for 2 h, was added to 200 g/ml and incubated
overnight at 37 °C. Samples were then re-extracted in SDS,
purified as above, lyophilized, and stored at 
20 °C. O-Acety-
lation levels of lyophilized PG were evaluated as a ratio of total
saponified O-linked acetate relative to total MurNAc content
using mild base-catalyzed release of O-linked acetate (0.1 M
NaOH, 40 °C for 4 h) and acid-catalyzed hydrolysis (6 N HCl,
100 °C for 1.5 h) for the complete liberation of PGmonosaccha-
rides, acetate, and muramic acid content. Components were
quantified by HPLC as described previously (49, 50).
PG Isolation and Muropeptide Analysis—Each strain was
grown on 20–25 MH-T plates (supplemented with Km as
required) for 18–20 h to standardize growth phase and har-
vested with ice-cold MH-TV broth. Strains were assessed by
DICM for contamination and coccoid cells to ensure that cul-
tures had not grown into stationary phase. Cells were lysed
using the boiling SDS technique as described previously (19).
PG was further purified from the cell lysate and digested with
the muramidase cellosyl (kindly provided by Hoechst, Frank-
furt, Germany). The muropeptides were reduced with sodium
borohydride, and subsequently separated by HPLC, all as
described previously (81). Muropeptide structures were
assigned based on (i) comparison with retention times of known
muropeptides fromC. jejuni and (ii) bymass spectrometry (Fig. 2)
(18, 19, 82).
Expression, Purification, and Biochemical Assays of C. jejuni
Ape1-His6—Cjj81176_0638 (encoding ape1) was PCR-ampli-
fied without the predicted 21-amino acid signal peptide (as
TABLE 5
Bacterial strains or plasmids used in this study
Strain or plasmid Genotype or description Source
C. jejuni strains
81-176 Wild-type isolated from diarrheic patient 87
ape1 81-176 ape1::aphA3;KmR This study
patB 81-176 patB::aphA3;KmR This study
patA 81-176 patA::aphA3;KmR This study
oap 81-176 oap::aphA3;KmR This study
ape1C 81-176 ape1 rrn::ape1 (from pRRC-0638) This study
patBC 81-176 patB rrn::patB (from pRRC-0639) This study
patAC 81-176 patA rrn::patA (from pRRC-0640) This study
E. coli strains
DH5- F
, 80d deoR lacZM15 endA1 recA1 hsdR17(rK-mK) supE44 thi-1 gyrA96 relA1
(lacZYA-argF) U169
Invitrogen
BL21(DE3) F
 ompT hsdSB(rB
, mB
) gal dcm  DE3 Novagen
Plasmids
pGEM-T High copy, linearized, T-tailed, Blue/White, ApR Promega
pUC18-K2 Source of non-polar aphA3 cassette; ApRKmR 47
pGEM-T-0638 pGEM-T ligated to 0638 amplified with 0637-2 and 0639-5 (2113 bp); ApR This study
pGEM-0638::aphA-3 pGEM-T-0638 inverse PCR amplified with 0638-3 and 0638-2 (4098 bp) and ligated to
aphA-3 (KpnI, HincII); ApR, KmR
This study
pGEM-T-0639 pGEM-T ligated to 0639 amplified with 0639-1 and 0639-2 (2146 bp); ApR This study
pGEM-0639::aphA-3 pGEM-T-0639 inverse PCR amplified with 0639-3 and 0639-4 (4267 bp) and ligated to
aphA-3 (KpnI, HincII); ApR, KmR
This study
pGEM-T-0640 pGEM-T ligated to 0640 amplified with 0639-6 and 0641-4 (2396 bp); ApR This study
pGEM-0640::aphA-3 pGEM-T-0640 inverse PCR amplified with 0640-1 and 0640-2 (4168 bp) and ligated to
aphA-3 (KpnI, HincII); ApR, KmR
This study
pGEM-0638–40::aphA-3 pGEM-T ligated to 0637 fragment amplified with 0637-1 and 0638-1 (1483 bp), 0641
fragment amplified with 0641-1 and 0641-2 (822 bp), and aphA-3 (KpnI, HincII);
ApR, KmR
This study
pRRC C. jejuni rRNA spacer integration vector; CmR 48
pRRC-0638 pRRC ligated to 0638 amplified with 0638-C1(NheI) and 0638-C2(MfeI) (1347 bp); CmR This study
pRRC-0639 pRRC ligated to 0639 amplified with 0639-C1(NheI) and 0639-C2(MfeI) (1276 bp); CmR This study
pRRC-0640 pRRC ligated to 0640 amplified with 0640-C1(NheI) and 0640-C2(MfeI) (1616 bp); CmR This study
pET28a() Commercial vector for expression of recombinant His6-tagged protein Novagen
p0638-His6 pET28a() ligated to ape1 amplified with 0638-eCF (NcoI) and 0638-eCR (EcoRI) (1121
bp) for expression of C-terminal His6-tagged 0638; KmR
This study
pHis6-0638 pET28a() ligated to ape1 amplified with 0638-eNF (NheI) and 0638-eNR (EcoRI)
(1116 bp); for expression of N-terminal His6-tagged 0638 KmR
This study
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identified by SignalP 4.1 Server) (83) and cloned into the
pET28a() (Novagen) expression vector in-frame with the
encoded His6 tag at either the N or C termini of the gene form-
ing pHis6-0638 and p0638-His6, respectively (Fig. 3, A and B).
Expression constructs were transformed into E. coli
BL21(DE3), selected for KmR, and confirmed by PCR and
sequencing. Expression and isolation of recombinant Ape1 are
described in the supplemental text S2.
Acetylesterase activitywas determined using pNPAc as a col-
orimetric substrate, as described previously (45). Assays were
performedwith 2.5g/ml purified Ape1-His6 in 50mM sodium
phosphate buffer, pH 6.5, and 2 mM pNPAc. Reactions were
monitored over 5 min, and specific activity was calculated with
an experimentally determinedmolar absorptivity of 3.42mM
1
cm
1 for p-nitrophenol (room temperature at pH 6.5).
PG-O-acetylesterase activity was tested using purified PG
retaining O-acetyl groups (as described under “PG Isolation
and Assessment ofO-Acetylation Levels”). Lyophilized PG was
resuspended in sodium phosphate buffer, pH 6.5, to a concen-
tration of 5 mg/ml and sonicated on ice with a microtip for 2
min (10 s on/10 s off). 500 l of PG suspension was aliquoted
into Eppendorf tubes to which, Ape1-His6 was added to a con-
centration of 10 g/ml (buffer only for negative control). Sam-
ples were incubated at 37 °C in awater bath for 24 h, after which
samples were centrifuged (10 000 	 g, 10 min, 4 °C) to pellet
PG. Acetate content in supernatants were assessed using a
commercial acetic acid assay kit (Megazyme International) as
directed by the manufacturer.
Microscopy and CellTool Shape Analysis—Overnight
MH-TV log-phase broth cultures were standardized to A600
0.05 and incubated for 4 or 7 h at 38 °C to generate early-expo-
nential phase andmid-exponential phase cultures, respectively.
The samples were processed for DICM. Live cells were imaged
on agarose slabs on a Nikon Eclipse TE2000-U microscope
equipped with a Hamamatsu C4742-95 digital camera.
For CellTool analysis (53), DICM images from multiple
fields (yielding 400 cells per strain) were taken for each
sample and processed by thresholding to generate binary
images. Artifacts and cells that were clumped or ill-repre-
sented based on lighting were manually removed. The con-
tours of the wild-type population were aligned to generate an
average shape, and PCA was performed to generate a “shape
model” based off principal components called “shape modes”
that, together, describe at least 95% of the variation in the wild-
type population. Contours of other strains were then aligned to
the wild-type PCA shape model as a reference. Kolmogorov-
Smirnov tests were used on each shape mode to determine
whether there was a statistically significant difference in popu-
lation distribution between the strains based on this wild-type
shape model (53).
Phenotypic Characterization of OAP Mutants: Motility, Bio-
film, Minimum Inhibitory/Bactericidal Concentrations and
Cell Surface Hydrophobicity—Motility and biofilm formation
assays were performed on log-phase bacterial broth cultures as
described previously (19).
MIC50 was determined in a 96-well plate as standing cul-
ture as described previously (84). Inocula of log-phase over-
night cultures (100 l) standardized to A600 0.0002 (106
CFU/ml) in MH-TV and 11 l of 10	 concentrated test
compound (in 2	 serial dilutions) were added to each well.
A600 was measured for each well using the Varioskan Flash
Multimode Plate Reader (Thermo Scientific), andMIC50 was
recorded as the lowest concentration of compound that
reduced growth by 50% (by turbidity) relative to a positive
control after 24 h.
Cell surface hydrophobicity was assessed using exponential
phase bacterial broth cultures as described previously (85) with
the following adjustments. Cultures were harvested at 8 000	
g for 10min andwashed three times with PBS. Cells were resus-
pended to an A600 0.5 in PBS, and the absorbance was
recorded.Hexadecanewas added to the standardized cultures in a
ratio of 1:4hexadecane/cultureby volume, vortexed for 5min, and
incubated at 38 °C for 30 min. The aqueous layer was isolated,
aerated by bubblingN2 gas through the aqueous layer for 30 s, and
left open to the air for 10 min to ensure removal of all traces of
hexadecane, and the A600 was measured. Cell surface hydropho-
bicity was expressed as follows, whereA600i andA600f refer to the
optical densities before and after extraction, respectively.
% Hydrophobicity  A600i 	 A600fA600i  
 100% (Eq. 1)
Chick Colonization—Chick colonization was assessed
under protocol 10462 approved by the University of Michi-
gan Committee on Care and Use of Animals, as described
previously (19, 79).
Gentamicin Protection Assay for Host-Cell Infection—Gm
protection assays were performed essentially as described pre-
viously (86). INT407 human epithelial cells were seeded into
24-well tissue culture plates at 1.25 	 105 cells in minimum
essential medium (MEM) supplemented with 10% (v/v) FBS
and 1	 penicillin/streptomycin (Gibco, Life Technologies,
Inc.) 24 h prior to infection. Infections were initiated by adding
log-phase bacterial cultures standardized toA600 0.002 inMEM
(1	 107CFU/ml) and added to INT407 cells previouslywashed
twice with 1 ml of MEM to give a multiplicity of infection of
80. Adherence/invasion after 3 h of infection, invasion fol-
lowing a 2-h Gm treatment (150 g/ml) to kill extracellular
bacteria, and intracellular survival following removal of the
highGmconcentration and incubation of cells in freshmedium
with 10 g/ml Gm and 3% FBS for an additional 3 h were
assessed as described (86).
Interleukin-8 Quantification—The concentration of IL-8
secreted by INT407 cells either left uninfected or infected with
C. jejuniwild-type strain 81-176,ape1, orape1C for 24 hwas
assayed using the human IL-8 ELISA kit (Thermo Fisher Scien-
tific) as described previously (18).
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Text S1. Deletion and complementation of OAP mutants 
Genes were PCR amplified using iProof™ (Bio-Rad) with primers designed to include 500-600 
bp of flanking DNA on either side of each gene (for PCR primers used for each gene, refer to Table S1). 
PCR products were adenylated at the 3’-ends using Taq DNA Polymerase (Invitrogen) and ligated to 
commercial cloning vector pGEM-T (Promega), resulting in pGEM-T-0638, pGEM-T-0639, and pGEM-
T-0640. Vectors were transformed into E.coli DH5-α and selected for ApR resistance and blue/white 
screening. All constructs were verified by sequencing and restriction digestion. The resulting constructs 
were inverse PCR amplified using primers designed to amplify the flanking regions and pGEM-T vector 
without the target gene save for the sequences used for primer design at the 5’ and 3’ ends of each gene 
(for PCR primers used for each gene, refer to Table S1).Approximately 86% of cjj81176_0638, 87% of 
cjj81176_0639, and 89% of cjj81176_0640 were deleted by inverse PCR. Inverse products were 
restriction digested where appropriate with sites encoded within the primers and ligated to the non-polar 
KmR cassette (aphA-3) digested out of pUC18K-2 (1) with KpnI and HincII to form the deletion-
constructs pGEM-0638::aphA-3, pGEM-0639::aphA-3, and pGEM-0640::aphA-3. To generate pGEM-
0638-40::aphA-3 deletion construct, the primers 0637-1/0638-1(KpnI) and 0641-1(NcoI)/0641-2(KpnI) 
were used to amplify the regions downstream and upstream of the OAP operon, respectively. The 
downstream PCR product was adenylated, ligated to pGEM-T, digested with KpnI and NcoI and ligated 
to the upstream PCR product (digested with KpnI and NcoI) generating pGEM-T-0637+0641. The aphA-
3 from pUC18K-2 (KpnI and HincII digested) was ligated to pGEM-T-0637+0641 digested with KpnI 
and SmaI resulting in pGEM-T-0638-40KmR and led to a deletion construct in which 98% of the putative 
oap operon was replaced by aphA-3. C. jejuni 81-176 was naturally transformed with each deletion 
construct. Mutant strains were selected by KmR and verified by PCR, restriction digestion, and 
sequencing. 
Genes were complemented using the pRRC system for gene delivery and expression (2). The 
genes cjj81176_0638, cjj81176_0639, and cjj81176_0640 were each individually PCR amplified using 
the complementation primers (denoted with a C in the primer name after the gene designation in Table 
S1). PCR products and pRRC vectors were restriction digested with MfeI/NheI and XbaI/NheI, 
respectively and ligated together. Resulting complementation constructs were transformed into E.coli 
DH5α via heat shock, selected for resistance to CmR on LB-CmR agar plates and confirmed by PCR and 
sequencing. Complementation constructs were naturally transformed into their respective mutants with 
the exception of pRRC-0638 which was first methylated before transformation into Δape1. Successful 
transformants were confirmed by PCR (Cat-2 and corresponding reverse complement primers designated 
 S-2 
 
with C2, Table S1) (3) and the rRNA locus of each insertion was confirmed using ak233, ak234 and 
ak235 primers specific to each of the three ribosomal spacer regions combined with the  C2 primers 
(Table S1) (2). 
Text S2. Cloning of Ape1 for Expression and Purification 
The ape1 gene was PCR amplified using primer pairs 0638-His-NF/0638-His-NR and 0638-His-
CF/0638-His-CR for insertion into pET28a(+) in frame with the encoded N-terminal and C-terminal 
6xHis tags, respectively to yield pHis6-0638 and p0638-His6 respectively. Primer 0638-His-NF was 
designed with an NheI restriction site for insertion downstream of pET28a(+) encoded 6xHis tag and 
thrombin cleavage site and will amplify cjj81176_0638 starting after the signal sequence predicted by 
SignalP 4.1. Primer 0638-His-NR is designed with an EcoRI restriction site for cloning into the MCS and 
contains the originally coded TAA stop codon. Primer 0638-His-CF was designed with an NcoI 
restriction site, that contains an AUG start codon and will amplify cjj81176_0638 starting after the signal 
sequence predicted by SignalP 4.1. Primer 0638-His-CR is designed with an EcoRI restriction site for 
cloning into the MCS and does not encode a stop codon allowing for translation through to the 6xHis tag 
followed by a TGA stop codon encoded in the pET28a(+) expression vector.  
Expression vectors were transformed into E. coli BL21 for expression. BL21-pET28a(+), BL21- 
pHis6-0638 , and BL21- p0638-His6were grown overnight under standard conditions with Km, as 
required. Strains from overnight cultures were subcultured to an OD600 of 0.2 and grown to OD600 of 
~0.5-0.6 before induction with 1 mM IPTG at room temperature for 3 hrs. Bacterial lysates were prepared 
by sonication for 2 mins (10s On/ 10 s OFF) in Lysis Buffer 1 (50 mM sodium phosphate buffer pH~8.0, 
300 mM NaCl, 10 mM imidazole) and recombinant Ape1 was purified by Ni-NTA agarose (Qiagen) 
affinity chromatography. The sample was washed twice with 4 mL of Wash Buffer 1 (20 mM imidazole, 
50 mM sodium phosphate buffer pH 8.0, 300 mM NaCl), once with 4 mL of Wash Buffer 2 (35 mM 
imidazole, 50 mM sodium phosphate buffer pH 8.0, 300 mM NaCl), and eluted with elution buffer (200 
mM imidazole, 50 mM sodium phosphate buffer pH 8.0, 300 mM NaCl). Purified protein was dialyzed 
against 250 x sample volume of dialysis buffer (50 mM sodium phosphate buffer pH 8.0, 30 mM NaCl) 
using Slide-A-Lyzer (ThermoScientific) at 4 ᵒC. The dialysis buffer was changed twice over 36 hrs. The 
sample was recovered and any precipitate present was removed via centrifugation. Quantification of total 
soluble protein was performed with Bio-Rad Dc Protein Assay Kit or by measuring the absorbance at 280 
nm on a Nanodrop (ND-1000, ThermoScientific). Samples were concentrated using 3K MWCO 
(Millipore) as directed and concentrated samples were flash frozen in liquid N2 as 10μL aliquots for 
storage at -80ᵒC until required.   
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Table S1. List of Primers used in this study with underlined restriction sites in lowercase  
Primer1 
(Source) 
Sequence  
(5’ to 3’) 
Restriction 
Site 
Δape1  
0637-2 GGTGGAGCATTAAGCGGAA  
0639-5 GCCACCAATAAGGCTTTTATTAAAAACTC  
0638-2*  GAAggtaccTGAGTATGGAATCTATTGTGTCATTTGTATTTA KpnI 
0638-3* CTATGAGCTGATGGCTAAAAAGTTACT  
ΔpatB  
0639-1 GGCTAGATGGCATATCAGTCTTTC  
0639-2 GACCATTTGTTAATTTGTGTAGTTCTTAACTC  
0639-3* GAAggtaccCTACAACAACCAAGCCAAGCA KpnI 
0639-4* GTGGCGCAAGAGAAATGTCT  
ΔpatA  
0639-6 GACCAGTCAAAATAGGATTTATAAGAAAGG  
0641-4 GCAGCAAACTTATATCTTAGTATGAGTTCTT  
0640-2 * GAAggtaccGCTATCATTAAAATACTAAATTCTAGAGAAAAATA
AGTC 
KpnI 
0640-1* GAATCTCCATTTTTACTAAAACCTTTTATCATAGC  
Δoap  
0637-1 TGCAAGAAATGCAGCAAATTTAAATCC  
0638-1  GAAggtaccCTATGAGCTGATGGCTAAAAAGTTACT  KpnI 
0641-1  GGATACACAGTCGATGAACCTG  NcoI 
0641-2  GAAggtaccAcccgggCCTTCAATCCAAAGCGAGATTTG KpnI, SmaI 
Resistance Markers  
cat-2 (3) GTTTTTTGGATGAATTACAAGA  
aphA3-2 (3) CTATTTTTTGACTTACTGGGGA  
Complement  
0638-C1 GCGGCGgctagcCGCAAGAGAAATGTCTAAACTTTTATTAGAAC NheI 
0638-C2 GCGGCGcaattgCCCAGCAAGAATTTTTAAGAGCTAGATT MfeI 
0639-C1 GCGGCGgctagcCTTTTGGGGTTCTTTTTATGATCTATCCTTTA NheI 
0639-C2 GCGGCGcaattgTGAGTATGGAATCTATTGTGTCATTTGTATTTA  MfeI 
0640-C1 GCGGCGgctagcGGTATGTAAGCGAACAACACGAA NheI 
0640-C2 GCGGCGcaattgACCAAGCCAAGCACTATAATCAAAATAA MfeI 
Ribosomal 16S Markers  
ak233 (2) GCAAGAGTTTTGCTTATGTTAGCAC  
ak234 (2) GAAATGGGCAGAGTGTATTCTCCG  
ak235 (2) GTGCGGATAATGTTGTTTCTG  
Protein Expression  
0638-His-NF GCGGCGgctagcCAAAATTTAAATACAAATGACACAATAGATTC
CATACT  
NheI 
0638-His-NR GCGGCGgaattcTTAATAATCAATGATATTTTTTAAATCCTCGAG
TAACTT  
EcoRI 
0638-His-CF GCGGCGccatggGGCAAAATTTAAATACAAATGACACAATAGA NcoI 
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TTCCATACT  
0638-His-CR GCGGCGgaattcCCATAATCAATGATATTTTTTAAATCCTCGAGT
AACTT  
EcoRI 
1 An asterisk (*) after the primer name indicates primers used for inverse PCR amplification for 
generating deletion constructs. The letter C in the primer name indicates primers used to generate 
complementation constructs in pRRC vectors. His in the primer name indicates primers used to amplify 
Cjj81176_0638 for generating His-tagged protein expression constructs.  
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